It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Visceral leishmaniasis (VL) is one of the leading infectious diseases affecting developing countries. Colloidal gold-based diagnostic tests are rapid tools to detect blood/serum antibodies for VL diagnosis. Lack of uniformity in the performance of these tests in different endemic regions is a hurdle in early disease diagnosis. This study is designed to validate a serum-based dipstick test in eight centres of six countries, India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain with archived and fresh sera from 1003 subjects. The dipstick detects antibodies against Leishmania donovani membrane antigens (LAg). The overall sensitivity and specificity of the test with 95% confidence intervals were found to be 97.10% and 93.44%, respectively. The test showed good sensitivity and specificity in the Indian subcontinent (>95%). In Brazil, Ethiopia, and Spain the sensitivity and specificity of the dipstick test (83.78–100% and 79.06–100%) were better as compared to the earlier reports of the performance of rK39 rapid test in these regions. Interestingly, less cross-reactivity was found with the cutaneous form of the disease in Spain, Brazil, and Sri Lanka demonstrating 91.58% specificity. This dipstick test can therefore be a useful tool for diagnosing VL from other symptomatically similar diseases and against cutaneous form of leishmaniasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
 ; Ali, Nahid 1
 
; Ali, Nahid 1 1 CSIR-Indian Institute of Chemical Biology, Kolkata, India (GRID:grid.417635.2) (ISNI:0000 0001 2216 5074)
2 Visva-Bharati, Department of Biotechnology, Santiniketan, India (GRID:grid.440987.6) (ISNI:0000 0001 2259 7889)
3 Institute of Postgraduate Medical Education and Research, Kolkata, India (GRID:grid.414764.4) (ISNI:0000 0004 0507 4308)
4 Rajendra Memorial Research Institute of Medical Sciences, Patna, India (GRID:grid.203448.9) (ISNI:0000 0001 0087 4291)
5 School of Tropical Medicine, Kolkata, India (GRID:grid.418546.a) (ISNI:0000 0004 1799 577X)
6 B. P. Koirala Institute of Health Sciences, Dharan, Nepal (GRID:grid.414128.a) (ISNI:0000 0004 1794 1501)
7 University of Colombo, Faculty of Medicine, Colombo, Sri Lanka (GRID:grid.8065.b) (ISNI:0000000121828067)
8 Aggeu Magalhhaes Institute, Oswaldo Cruz Foundation, Recife, Brazil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
9 Universidade Federal do Piaui, Teresina, Brazil (GRID:grid.412380.c) (ISNI:0000 0001 2176 3398)
10 University of Gondar, Gondar, Ethiopia (GRID:grid.59547.3a) (ISNI:0000 0000 8539 4635)
11 Instituto de Salud Carlos III, Madrid, Spain (GRID:grid.413448.e) (ISNI:0000 0000 9314 1427)




